30 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
Icahn School of Medicine At Mount Sinai
Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers.
Rashtrasant Tukadoji Maharaj Nagpur University
Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.
Astex Pharmaceuticals
Discovery and characterization of novel allosteric FAK inhibitors.
Takeda Pharmaceutical
Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.
TBA
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
University of Oxford
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
RhôNe-Poulenc Rorer
Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.
Chemical Genomics Centre of The Max Planck Society
5,6,7,8-Tetrahydropyrido[4,3-d]pyrimidines as novel class of potent and highly selective CaMKII inhibitors.
Dainippon Sumitomo Pharma
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Ambit Biosciences
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
Novartis Institutes For Biomedical Research
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
Glaxosmithkline
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.
Griffith University
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
University of Florida
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.
Takeda Pharmaceutical
Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).
Moffitt Cancer Center
Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor.
Duke University Medical Center
Novel Indolocarbazole protein kinase C inhibitors with improved biochemical and physicochemical properties.
Tumor Biology Center